Descrizione del progetto
Un vaccino innovativo contro il cancro al pancreas
Il cancro al pancreas è una malattia mortale per cui non è disponibile alcun trattamento. CyTuVax B.V. è un’impresa biotecnologica che applica citochine depot per incrementare le risposte immunitarie quando vengono impiegate in una densità locale molto elevata. L’impresa ha sviluppato un’innovativa tecnologia che può essere applicata a qualsiasi vaccino e influenzarne la futura tecnologia. Il progetto PanCaVax, finanziato dall’UE, si concentrerà sullo sviluppo di un vaccino economicamente accessibile per il cancro al pancreas. Tale terapia dovrebbe notevolmente migliorare l’aspettativa di vita estendendo il tasso di sopravvivenza medio di almeno 12-24 mesi. Il progetto intende raggiungere un risultato clinico favorevole e una prova di efficacia sufficiente per le prossime tappe nella fase IIb/IIIa, l’approvazione normativa e l’accesso finale ai pazienti affetti da cancro al pancreas.
Obiettivo
CyTuVax B.V. is a biotech enterprise founded in Maastricht (the Netherlands) in October 2012. It applies depot-formulated
cytokines (interaction molecules of the immune system), which enhance immune responses in an unprecedented manner
when used in extremely high local density. Single and multi-cytokine combinations can be formulated by simple procedures
and act as strong adjuvants, driving immune responses to their limits. It is a universal, patented platform adjuvant technology
that can be applied to any vaccines and can have great influence on future vaccine technology. CyTuVax achieved the first
clinical proof of concept in a Phase I trial in which 90% of hepatitis B non-responders were successfully vaccinated. Phase II
is on-going. CyTuVax decided now to focus on the challenging problem of developing a vaccine for pancreatic cancer, a
deadly disease for which no curative treatment exists. Its cancer vaccination therapy (PanCaVax) should substantially
improve the life-expectancy by extending the median survival rate to at least 12-24 months. Costs of PanCaVax will be
considerably less compared to checkpoint inhibitor antibodies, with locally strong, but systemically mild, side effects
expected. CyTuVax’ highly motivated team’s next step is to complete the preclinical development of
PanCaVax. Key impact of our innovation would be that it is providing a favorable clinical outcome and sufficient proof of efficacy to obtain financial resources for next steps in Phase IIb/IIIa, regulatory approval and ultimate access to pancreatic cancer patients currently lacking an acceptable therapy.
Campo scientifico
Not validated
Not validated
- medical and health sciencesclinical medicinesurgery
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesbasic medicineimmunologyimmunotherapy
- medical and health sciencesclinical medicineoncologypancreatic cancer
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
6229 EV MAASTRICHT
Paesi Bassi
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.